HTG lands $10M in third round

High Throughput Genomics, an Arizona-based provider of microplate-based gene expression assay technology and services, has raised $10 million in its third round of financing. Merck's investment arm led the round. Also contributing were Solstice Capital, Valley Ventures and Arcturus Capital. HTG is hoping to develop a universal molecular biology-based tool set to improve the drug discovery process.

"Adoption of HTG's technology continues to rise, and we have diversified our portfolio of products and services including a strategic focus on academic collaborations, to best meet the evolving needs of our clients. With this new financing, HTG will be able to scale our sales and marketing activities to our growth," said E. William Radany, Ph.D., Chief Executive Officer, HTG.

- see this release
- read this Arizona Star report for more

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.